Literature DB >> 11221849

A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation.

A V Bazarov1, S Adachi, S F Li, M K Mateyak, S Wei, J M Sedivy.   

Abstract

Dergulation of c-myc and mutation of ras genes is commonly found in many human tumors. Several lines of evidence indicate that c-Myc and oncogenic Ras cooperate in causing malignant transformation, but the mechanism of this cooperation is not understood. We set out to investigate the effect on transformation of a modest reduction in endogenous c-Myc expression, which was achieved using a c-myc heterozygous cell line constructed by targeted homologous recombination. In contrast to previous reports where c-Myc expression or activity was ablated using antisense or dominant-defective methods, use of c-myc +/- cells provides a stable and homogeneous cell culture system with a precisely defined c-Myc expression level. In addition, this approach does not suffer from nonspecific artifacts such as antisense oligonucleotide toxicity or interference of dominant-defective proteins with multiple (and often undefined) target proteins. The striking and unexpected finding communicated here is that the relatively modest 50% reduction in c-Myc expression resulted in a greater than 10-fold reduction in susceptibility to transformation by oncogenic Ras or Raf proteins. This very significant defect in transformation potential cannot be explained on the basis of a generalized cell-cycle defect, because c-myc +/- cells exhibit only a minimal (20%) reduction in proliferation. Genetic epistasis analysis indicated that c-Myc and Ras acted by independent pathways that converged to regulate the abundance of the cyclin-dependent kinase inhibitor protein p27Kip1. Anchorage deprivation elicited a strong up-regulation of p27, and a 50% reduction in c-Myc expression significantly compromised the ability of Ras to down-regulate p27. We propose that Ras and c-Myc signals cooperate to regulate the activity of cyclin D-Cdk4/6 complexes: the former by up-regulating the expression of cyclin D1 and the latter by affecting the activity of the complexes. Ectopic expression of cyclin A restored the transformation potential of c-myc +/- cells, implicating it as a downstream genetic component in the pathway. From a therapeutic standpoint, it is of interest that, although transformation appears to be very sensitive to c-Myc expression levels, much larger reductions can be tolerated without causing any significant cell cycle defects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11221849

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Growth-promoting and tumourigenic activity of c-Myc is suppressed by Hhex.

Authors:  V Marfil; M Blazquez; F Serrano; J V Castell; R Bort
Journal:  Oncogene       Date:  2014-09-15       Impact factor: 9.867

Review 2.  Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.

Authors:  Chenguang Wang; Michael P Lisanti; D Joshua Liao
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

3.  Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis.

Authors:  T Bowman; M A Broome; D Sinibaldi; W Wharton; W J Pledger; J M Sedivy; R Irby; T Yeatman; S A Courtneidge; R Jove
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-12       Impact factor: 11.205

4.  Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.

Authors:  Franz X Schaub; Varsha Dhankani; Ashton C Berger; Mihir Trivedi; Anne B Richardson; Reid Shaw; Wei Zhao; Xiaoyang Zhang; Andrea Ventura; Yuexin Liu; Donald E Ayer; Peter J Hurlin; Andrew D Cherniack; Robert N Eisenman; Brady Bernard; Carla Grandori
Journal:  Cell Syst       Date:  2018-03-28       Impact factor: 10.304

5.  Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia.

Authors:  Michael A Linden; Nicole Kirchhof; Cathy S Carlson; Brian G Van Ness
Journal:  Exp Hematol       Date:  2011-11-23       Impact factor: 3.084

6.  Psoralen-modified clamp-forming antisense oligonucleotides reduce cellular c-Myc protein expression and B16-F0 proliferation.

Authors:  D A Stewart; S D Thomas; C A Mayfield; D M Miller
Journal:  Nucleic Acids Res       Date:  2001-10-01       Impact factor: 16.971

7.  Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas.

Authors:  Irene Ischenko; Oleksi Petrenko; Michael J Hayman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

8.  Regulation of APC(Cdh1) E3 ligase activity by the Fbw7/cyclin E signaling axis contributes to the tumor suppressor function of Fbw7.

Authors:  Alan W Lau; Hiroyuki Inuzuka; Hidefumi Fukushima; Lixin Wan; Pengda Liu; Daming Gao; Yi Sun; Wenyi Wei
Journal:  Cell Res       Date:  2013-05-14       Impact factor: 25.617

Review 9.  MYC oncogene in myeloid neoplasias.

Authors:  M Dolores Delgado; Marta Albajar; M Teresa Gomez-Casares; Ana Batlle; Javier León
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

10.  The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects.

Authors:  Sara Ota; Zi-Qiang Zhou; Jason M Link; Peter J Hurlin
Journal:  Hum Mol Genet       Date:  2009-04-29       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.